Tag Archives: Brian Abrahams

RBC Capital Thinks Karyopharm Therapeutics’ Stock is Going to Recover

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on April 8 and set a price target of $24.00. The company’s shares closed last Friday at $10.02, close to its 52-week low of

Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Global Blood Therapeutics (GBT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Global Blood Therapeutics (GBT – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) RBC Capital

RBC Capital Keeps Their Buy Rating on Metacrine (MTCR)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Metacrine (MTCR – Research Report) on March 18 and set a price target of $25.00. The company’s shares closed last Friday at $8.09, close to its 52-week low of $7.64.

Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX) and Dicerna Pharma (NASDAQ: DRNA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Theratechnologies (THTX – Research Report) and Dicerna Pharma (DRNA – Research Report). Theratechnologies (THTX) In a report issued on January 29, Brian Abrahams

NeuBase Therapeutics (NBSE) Gets a Buy Rating from RBC Capital

RBC Capital analyst Brian Abrahams reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) on December 23 and set a price target of $17.00. The company’s shares closed last Thursday at $7.64. According to TipRanks.com, Abrahams is a

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), BeiGene (NASDAQ: BGNE) and iTeos Therapeutics (NASDAQ: ITOS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report), BeiGene (BGNE – Research Report) and iTeos Therapeutics (ITOS – Research Report). Biogen (BIIB) RBC Capital analyst Brian